9-aminocamptothecin has been researched along with Neoplasm Metastasis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W | 1 |
Goldberg, RM; Hatfield, AK; Knost, JA; Krook, JE; Kugler, J; Mahoney, MR; Pitot, HC; Sargent, DJ | 1 |
2 trial(s) available for 9-aminocamptothecin and Neoplasm Metastasis
Article | Year |
---|---|
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome | 1997 |
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors | 2000 |